Stockreport

Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3 [Seeking Alpha]

Tarsus Pharmaceuticals, Inc.  (TARS) 
PDF Xdemvy remains the only approved treatment for Demodex blepharitis, with accelerating sales growth and significant untapped patient population in the U.S. TARS is poi [Read more]